MediWound's innovative medicinal product, NexoBrid™, is an investigational burn wound eschar removal agent currently being studied in patients with deep partial and/or full thickness burns. NexoBridTM completed phase 2 and phase 3 clinical studies and it's marketing authorization application is currently under review by the European Medicine Agency.
MediWound's innovative medical device, PolyHeal™, is CE marked device indicated for the treatment of wounds. For more information about PolyHeal™, please visit the product web site at: www.PolyHeal.com
MediWound operates a cGMP and ISO13485 manufacturing facility for sterile pharmaceutical products and medical devices that meets high quality requirements.
MediWound's goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™ and wound treatment medical device PolyHeal™, in order to improve wound management and achieving better outcomes.
NexoBrid™ is an innovative enzymatic product under investigation for eschar removal of burn wounds which may provide an alternative to current eschar removal means, such as surgery or non-surgical methods and be inline with current medical trends of minimally invasive modalities.
